Exenatide Once Weekly Versus Daily Basal Insulin as Add-on Treatment to Metformin With or Without a Sulfonylurea: A Retrospective Pooled Analysis in Patients With Poor Glycemic Control

References

• . Inzucchi SE, Bergenstal RM, Buse JB, ; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Buse JB, Taylor K, ; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250
   PubMed Web of Science ®Google Scholar
• . Bergenstal RM, Wysham C, Macconell L, ; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–439
   PubMed Web of Science ®Google Scholar
• . Diamant M, Van Gaal L, Stranks S, . Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234–2243
   PubMed Web of Science ®Google Scholar
• . Russell-Jones D, Cuddihy RM, Hanefeld M, ; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252–258
   PubMed Web of Science ®Google Scholar
• . Blevins T, Pullman J, Malloy J, . DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–1310
   PubMed Web of Science ®Google Scholar
• . Buse JB, Rosenstock J, Sesti G, ; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47
   PubMed Web of Science ®Google Scholar
• . Buse JB, Nauck M, Forst T, . Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2011;381(9861):117–124
   Google Scholar
• . Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29(3):554–559
   PubMed Web of Science ®Google Scholar
• . Bydureon [prescribing information]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2012
   Google Scholar
• . Davies M, Heller S, Sreenan S, . Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care. 2013;36(5):1368–1376
   PubMed Web of Science ®Google Scholar
• . Macconell L, Pencek R, Li Y, Maggs D, Porter L. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes. 2013;6:31–41
   PubMedGoogle Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143(8):559–569
   PubMed Web of Science ®Google Scholar
• . Barnett AH, Burger J, Johns D, . Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29(11):2333–2348
   PubMed Web of Science ®Google Scholar
• . Bunck M, Diamant M, Cornér A, . One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32(5):762–768
   PubMed Web of Science ®Google Scholar
• . Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab. 2009;11(12):1153–1162
   PubMed Web of Science ®Google Scholar
• . Russell-Jones D, Vaag A, Schmitz O, ; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–2055
   PubMed Web of Science ®Google Scholar
• . Diamant M, Peters A, Russell-Jones D, . Is insulin the most effective injectable HbA1c-lowering therapy [EASD abstract 800]? Diabetologia. 2012;55( suppl 1):S329–S30
   Google Scholar
• . Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care. 2006;29(9):2137–2139
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27(3):309–317
   PubMed Web of Science ®Google Scholar
• . Henry RR, Buse JB, Sesti G, . Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. Endocr Pract. 2011;17(6):906–913
   PubMedGoogle Scholar
• . Anderson SL, Trujillo JM, McDermott M, Saseen JJ. Determining predictors of response to exenatide in type 2 diabetes. J Am Pharm Assoc (2003). 2012;52(4):466–471
   PubMedGoogle Scholar